- In August 2023, The U.S. FDA granted accelerated approval to Pfizer's Elrexfio (elranatamab), a bispecific antibody targeting BCMA-expressing multiple myeloma cells. This provides a novel option for patients with relapsed or refractory multiple myeloma
- In April 2023, the FDA approved Omisirge (omidubicel-onlv), a cord blood-derived stem cell therapy, for use in adult and pediatric patients (12 years and older) with hematologic malignancies (blood cancers) who are planned for umbilical cord blood transplantation following myeloablative conditioning. This approval was specifically aimed at reducing the time to neutrophil recovery and the incidence of infection post-transplantation
- In March 2024, Breyanzi, a CAR-T cell therapy, received FDA approval for treating chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), adding to its prior approvals for large B-cell lymphoma
- In March 2023, Pfizer announced its definitive merger agreement to acquire Seagen Inc., a global biotechnology company specializing in transformative cancer medicines, for approximately USD 43 billion in cash. The acquisition was successfully completed in December 2023 after receiving necessary regulatory approvals
